Anestimated9millionindividualsarechronicallyinfectedwithhepatitisBvirus(HBV) andhepatitisCvirus(HCV)acrosstheEuropeanUnion/EuropeanEconomicArea(EU/ EEA),manyofwhichareyettobediagnosed.Weperformedasystematicreviewto identifyinterventionseffectiveatimprovingtestingofferanduptakeintheEU/EEA. Originalresearcharticlespublishedbetween1January2008and1September2017 wereretrievedfromPubMedandEMBASE.SearchstringscombinedtermsforHBV/ HCV, intervention, testing and geographic terms (EU/EEA). Out of 8331 records retrieved, 93 studies were selected. Included studies reported on testing initiatives in primaryhealthcare(9),hospital(12),otherhealthcaresettings(31)andcommunitysettings(41).Testinginitiativestargetedpopulationgroupssuchasmigrants,drugusers, prisoners, pregnant women and the general population. Testing targeted to populations at higher risk yielded high coverage rates in many settings. Implementation of novel testing approaches, including dried blood spot (DBS) testing, was associated with increased coverage in several settings including drug services, pharmacies and STIclinics.Community-basedtestingserviceswereeffectiveinreachingpopulations at higher risk for infection, vulnerable and hard-to-reach populations. In conclusion, ourreviewidentifiedseveralsuccessfultestingapproachesimplementedinhealthcare andcommunitysettings,includingtestingapproachestargetinggroupsathigherrisk, community-basedtestingservicesandDBStesting.Combiningadiversesetoftesting opportunitieswithinnationaltestingstrategiesmayleadtohigherimpactbothinterms oftestingcoverageandintermsofreduction,ontheundiagnosedfraction. K E Y W O R D S Europe,hepatitisB,hepatitisC,screening,testing ThisisanopenaccessarticleunderthetermsoftheCreativeCommonsAttributionLicense,whichpermitsuse,distributionandreproductioninanymedium, providedtheoriginalworkisproperlycited.
| INTRODUC TI ON
AcrosstheEuropeanUnion/EuropeanEconomicArea(EU/EEA),an estimated4.7millionpeoplearechronicallyinfectedwithhepatitis B virus (HBV) and 3.9 million are chronically infected with hepati-tisCvirus(HCV). 1 HBVandHCVcanbothcauseacuteandchronic hepatitis, potentially leading to the development of cirrhosis, liver cancerordeathofinfectedpatients. 2, 3 Earlydiseaseanddevelopmentofliverdamageareoftenasymptomatic, [4] [5] [6] meaningthatHBV and HCV infection may go undetected for many years 7 and many infectedpeopleremainundiagnosed. 8 Transmission of HBV and HCV can occur sexually, through blood-to-blood contact or vertically (mother-to-child). Over the past decades, there have been shifts in the patterns of transmission in Europe, due to various factors, including improvements in bloodtransfusionandhealthcaresafetystandards,HBVvaccination programmes, harm reduction programmes targeting injecting drug use,aswellassignificantchangesinpatternsofinjectingdruguse andimmigration.However,anumberofpopulationgroupsarestill potentially at high risk or have a high burden of HBV/HCV in EU/ EEAcountries,includingpeoplewhoinjectdrugs(PWID),menwho havesexwithmen(MSM),peoplelivingwithHIV(PLHIV),peoplein prisonandmigrantsfromcountriesofhighendemicity. [9] [10] [11] As highly effective treatment options have become available for HBV and HCV, 12, 13 it is crucial that an informed public health response is in place tailored to the local epidemiological situation, which will ensure that those infected are diagnosed and linked to care.Estimatesoftheundiagnosedfractioninthegeneralpopula-tioninEU/EEAcountriesrangefrom40%to85%forHBVand20% to 91% for HCV, with large variability between countries. 11 The WHOhasformulatedanactionplantoeliminateviralhepatitisasa publichealththreatintheEuropeanregionby2030,settingtargets of50%ofpeoplewithchronicinfectiondiagnosedby2020and90% by 2030. 14 A systematic review covering HBV and HCV testing studies in keypopulationsintheEuropeanregionuntilJune2013foundthat, although a large number of studies on testing existed, these were unevenly distributed across Europe and that large gaps existed in certain key populations including migrants, people in prison and MSM. 17 Previous systematic reviews on testing interventions focused solely on either HBV or HCV, [18] [19] [20] [21] [22] [23] specific key populations or settings, 19, 21, 22, 24 targeted testing interventions 18, 23 or included comparativestudiesonly. 25 Finally,acomprehensivereportonhepatitis testing policies and activities in EU/EEA countries revealed substantialgapsintestingcoverageandtestingofferstargetingspecificallyhigherriskgroupsacrosstheregion. 8 The scope of this study was to provide an overview of different effective testing strategies for hepatitis B and C and their outcomes in the EU/EEA, covering all relevant population groups and settings. 
| Definitions

| Data extraction and quality assessment
Relevant data were extracted from included articles and recorded inadataextractionfileinMicrosoftExcel.Apredefinedsetofvariables covering study characteristics, study population details and outcomes was extracted per study. Asetofdetailedsummarytablesweredevelopedpersetting(provided in Tables S7-S11), containing the following information: study reference,country,studyperiod,studydesign,studypopulationand specificsetting,samplesize,outcomes(testoffer,coverageandpositivity rate, acceptance rate and patient and provider indicators of acceptabilityandfeasibility),criticalappraisalandcomments.Within each table, findings are ordered by virus, study population, country andyearofpublication. 
| RE SULTS
| Testing initiatives in primary healthcare settings
Nine studies that reported outcomes on testing initiatives performedinprimaryhealthcaresettingswereretrieved [28] [29] [30] [31] [32] [33] [34] [35] [36] (Table1). HBV/HCVtestofferrates,coverageandpositivityrates,wherereported,rangedwidelybetweenstudies.Thehighestofferrateand coveragereportedwas70%and100%,respectively,inastudytargetingmigrants. 30 VeryhighpositivityratesforHCVwerereported ininitiativestargetingPWID(70%)andhomelesspeople(26%). 29, 33 TwoinitiativestargetingmigrantsreportedHBVandHCVpositivity ratesof0%. 30, 32 One comparative study on HCV risk group testing in PWID reported testing coverage of 24.8% among PWID in GP practices exposedtotheintervention,comparedto0.3%ofPWIDtestedin comparablecontrolpractices. 29 Inacomparativestudyonbirthco-horttestingforHCVtestinginanareaofhighprevalenceofHCV andintravenousdruguse,72%of30-to54-year-oldswereoffered testing, compared to 0% in a control practice in the same area wherebirthcohorttestingwasnotimplemented. 28 Inanadditional comparativestudy,thenumberoftestsperformedincreasedfrom 5421beforeto10117duringanationaltestingprogrammewhich involved awareness-raising activities for GPs and those at higher risk. 34 Another comparative study found a significant increase in the number tested when a public awareness campaign was com- 
| Testing initiatives in hospital settings
Twelve studies were identified on the effectiveness of testing initiatives and interventions in hospital settings 34, 35, [37] [38] [39] [40] [41] (Table 2 ). Test offerrates,coverageandHBV/HCVpositivityratesvariedwithhigh offerrates(83%and100%)intestinginitiativestargetedatmigrants and psychiatric patients. 37, 40, 41 Coverage was highest (88.4%) in a studyreportingonauniversaltestinginitiativeconductedatasingle emergencydepartment. 38 Aseparateuniversaltestinginitiativeconductedinmultipleemergencydepartments,however,yieldedamuch loweroverallcoverageof27%,althoughwithvariationsamongtesting sites. 39 PositivityratesforHBVandHCVwerehigherinstudiesreportingoninitiativestargetedatkeypopulations(2.2%-7.8%forHBVand 0.3%-8.7%forHCV)thanthoseaimedatthegeneralpopulation. 37, 40, 41 Onecomparativestudyreportedonimplementationoforalsam-plingforHCVtestingbetween2011and2014. 35 
| Testing initiatives in other healthcare settings
Thirty-one studies were included relating to other healthcare settings 34, 35, (Table 3) Community-based testing services, both fixed-site and outreach-based, represent potential sites to target specific population groups and individuals who may be at increased risk of infectionandwhoarenotincontactwithformalhealthservices.
| Testing initiatives in community settings
Testing in community settings can be adapted and made accessible for these groups in order to maximize testing uptake 15 
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